Systemic Sclerosis: A Hard Approach in a Hardened Skin
Helena Marques* and Cristina Ferreira Tavares
USF S. Félix/Perosinho, São Félix da Marinha, Espinho, Portugal

Abstract
Systemic sclerosis (SSc) is a multisystem disease characterized by widespread vascular dysfunction and progressive fibrosis of the skin and internal organs. SSc’s prevalence ranges from 30 to 240 per million inhabitants, being females mostly affected. This case is about a female, 43 years old. Visited family doctor with complaints of fatigue, lumbago at nighttime and systemic myalgia. Pain, edema and thumb’s paresthesia persisting for a week preceding the time of the appointment. Physical examination showed edema of the distal phalanges bilaterally. No skin or nail changes were present. No signs of arthritis. Raynaud’s phenomenon with coarse speckle >1:160, normal ds-DNA and RF, sedimentation rate of 32 mm/h. The patient was referred to a rheumatology consultation. During one year of follow-up in rheumatology consultation, just kept arthralgia without other symptoms. In September 2014, the physical exam showed skin wrinkling in the distal ends of the fingers with positive Raynaud. New immunological study ANA, rheumatoid factor (RF), C3, C4, anti-centromere antibody (ACA), topoisomerase I (anti-Scl-70) and nailfold capillaroscopy were requested. Positive ANA, negative ACA and anti-Scl-70. Nailfold capillaroscopy showed dilated capillary loops, microhemorrhages and architectural derangement. Systemic sclerosis (SE) was diagnosed. Methotrexate and prednisolone treatment were initiated. Currently, progressive worsening of tissue fibrosis despite maximal immunosupression with methotrexate. Tocilizumad treatment under consideration. Annual follow-up with pulmonary function testing (PFT), lung CT and Doppler echocardiography.

Overlapping symptomatology with other diseases such as systemic lupus erythematosus (SLE), dermatomyositis and rheumatoid arthritis may occur. Therapy requires a systemic and multidisciplinary overview of the patient. It must be coherently adapted to target its manifestations, as to improve quality of life and prevent, when possible, disease progression.

Keywords: Systemic sclerosis; Scleroderma; Family medicine; Raynaud phenomenon

Introduction
Systemic sclerosis (SSc) is a multisystem disease characterized by widespread vascular dysfunction and progressive fibrosis of the skin and internal organs [1]. SSc is generally subdivided into limited (lcSSc) and diffuse (dcSSc) cutaneous subsets. Patients with lcSSc typically have skin involvement distal to the elbows and knees, and may display features of the CREST syndrome (calcinosis cutis, Raynaud phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia). Patients with dsSSc generally have skin involvement extending to the proximal limbs and/or trunk and are at a greater risk for the development of significant renal, lung, and cardiac disease [1-7].

SSc should be suspected in patients with skin thickening, puffy or swollen fingers, hand stiffness, and painful distal finger ulcers. Symptoms of Raynaud phenomenon and gastroesophageal reflux are often present [1,3].

The 2013 classification criteria for SSc were developed by a joint committee of the American college of rheumatology (ACR) and the European league against Rheumatism (EULAR). Incorporate disease manifestations of the three hallmarks of SSc: fibrosis of the skin and/or internal organs, production of specific autoantibodies, and evidence of vasculopathy [8,9].

The differential diagnosis in SSc includes scleroderma, scleromyxoedema, overlap syndromes, endocrine disorders, nephrogenic systemic fibrosis, amyloidosis, eosinophilic fasciitis, chronic graft-versus-host disease (GVHD), drug-induced scleroderma and environmental exposures [1,3,10,11].

All patients require symptomatic treatment and both limited and diffuse cases should be treated for vascular manifestations. Early dcSSc requires immunosuppressive treatment. In all cases of Ssc vigilant follow up to determine significant organ based complications is mandatory [3,7,10].

Methods
Interview/family evaluation with patient

Results

Personal background
• Female, 43 years old, married, public transport driver, stage 1 of Duval cycl, middle class according to Graffar scale, Appgar score corresponding to highly functional family.
• Pathological background: esophagitis, hiatus hernia and dyslipidemia.
• Surgical background: oophorectomy and tonsillectomy.
• No medicine or food allergies known.
• Up-to-date vaccination.
• Denied smoking, alcohol or drug abuse.
• No risky sexual behavior

Family background
• Father: psoriasis, diabetes mellitus type II and dyslipidemia.

*Corresponding author: Helena Marques, USF S. Félix/Perosinho, São Félix da Marinha, Espinho, Portugal, Tel: +351 22 753 6450; E-mail: helenac.marques@hotmail.com

Received August 24, 2016; Accepted September 24, 2016; Published September 30, 2016


Copyright: © 2016 Marques H, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Sinvastatin 20 mg once a day, omeprazole 40 mg once a day, methotrexate 25 mg once a week, prednisone 5 mg once a day, primrose oil twice a day, L-ascorbic acid

Current disease status

- **May 2013**: Visited family doctor with complaints of fatigue, lumbago at nighttime and systemic myalgia. Pain, edema and thumb’s paresthesia persisting for a week preceding the time of the appointment. Physical examination showed edema of the distal phalanges bilaterally. No skin or nail changes were present. No signs of arthritis. Raynaud’s phenomenon not conclusive. No constitutional symptom. Spine CT, hemogram, sedimentation rate, C-reactive protein (CRP), antinuclear antibody (ANA), anti-double-stranded (ds-DNA), rheumatoid factor (RF), creatine kinase (CK) and serum creatinine level examinations were requested. In case of emergency, treatment with etoricoxib was prescribed.

- **August 2013**: Evaluated on rheumatology consultation. Patient kept symptomatology. Arthralgia of inflammatory rate. Immunologic study, protein electrophoresis, iron kinetics, serology, chest X-ray and electromyography were requested.

- **October 2013**: No finger swelling, diffuse arthralgia of inflammatory rate. Exams show ANA (1/160) and negative RF. Electromyography shows bilateral mono-neuropathy by compression of the median nerve at the carpal tunnel. No changes observed in the other exams. Orthopedic consultation requested. Etoricoxib treatment showed no improvement. Therapeutic trial with Diprophos® prescribed.

- **March 2014**: Patient claimed transient improvement with Diprophos® but maintained complaints of hands paresthesia and excessive sweating at nighttime. Tuberousclerosis screening was requested.

- **September 2014**: Persisting symptomatology. Negative tuberculin test. The physical exam showed skin wrinkling in the distal ends of the fingers with positive Raynaud. New immunological study ANA, RF, C3, C4, anti-centromere antibody (ACA), topoisomerase I (anti-Scl-70) and nailfold capillaroscopy were requested. Anti-RNA polymerase III antibody was not requested due to exam unavailability.

- **November 2014**: Positive ANA, negative ACA and anti-Scl-70. Nailfold capillaroscopy showed dilated capillary loops, microhemorrhages and architectural derangement. Systemic sclerosis (SE) was diagnosed. Methotrexate and prednisolone treatment were initiated. Pulmonary function testing (PFT), lung CT, Doppler echocardiography, upper gastrointestinal endoscopy (UGI), esophageal manometry and 24 h pH monitoring was requested.

- **February 2015**: Worsening symptoms upon return to consultation. Skin thickening of the hands, face and forearms, perioral skin tightening with decreased oral aperture, digital pitting, and tendon friction rubs of the fingers and ankles and dysphagia with gastroesophageal reflux. Normal PFT and lung CT, pulmonary artery systolic pressure (PASP) 32 mmHg. Gastroesophageal reflux disease confirmed.

- **Currently**: Progressive worsening of tissue fibrosis despite maximal immunosuppression with methotrexate. Tocilizumad treatment under consideration. Annual follow-up with PFT, lung CT and Doppler echocardiography.

**Conclusion**

Systemic sclerosis is characterized by a heterogeneous phenotype, affecting various organs, rendering differential diagnosis challenging. The diagnosis is based on the presence of physical symptoms and changes of specific antibodies. Overlapping symptomatology with other diseases such as systemic lupus erythematosus (SLE), dermatomyositis and rheumatoid arthritis may occur. Therapy requires a systemic and multidisciplinary overview of the patient. It must be coherently adapted to target its manifestations, as to improve quality of life and prevent, when possible, disease progression.

In this particular case, diagnosis was challenging, with several hypothesis having been considered. The verification of the Raynaud’s phenomenon led to the complementary set of exams which allowed the final diagnosis of diffuse systemic sclerosis.

**References**